Alpha Tau to Participate in December Investor Conferences

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), an Israeli company pioneering in innovative cancer therapies, has announced its participation in two key investor conferences this December. CFO Raphi Levy will present at the 37th Annual Piper Sandler Healthcare Conference, scheduled for December 3, 2025, in New York, where he will engage in a fireside chat from 1:00 PM to 1:25 PM ET. Following this, Levy will present in a company presentation format at Sidoti's Year End Virtual Investor Conference on December 10, 2025, from 11:30 AM to 12:00 PM ET. Both venues will also provide opportunities for one-on-one investor meetings, allowing interested parties to schedule discussions through conference representatives.

Founded in 2016, Alpha Tau Medical focuses on the research and commercial development of its flagship product, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). This innovative therapy is designed specifically for the treatment of solid tumors, utilizing a unique methodology that involves intratumoral delivery of radium-224 sources. When radium-224 decays, it releases short-lived daughter isotopes, which emit high-energy alpha particles aimed at destroying tumor cells while minimizing damage to surrounding healthy tissue.

Alpha Tau's research has its roots in the work of Professors Itzhak Kelson and Yona Keisari from Tel Aviv University, positioning the company as a noteworthy player in the oncology sector. As they advance their pioneering alpha-radiation therapy, the upcoming investor conferences mark an important opportunity for Alpha Tau to engage with the investment community and share developments in their groundbreaking approach to cancer treatment. For further inquiries, investors can reach the company via their dedicated investor relations email at IR@alphatau.com.

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) is poised for an intriguing end to 2025 with its participation in the upcoming December investor conferences. As a company pioneering in the oncology space with its innovative Alpha DaRT® technology, Alpha Tau's presence at major conferences like the 37th Annual Piper Sandler Healthcare Conference and Sidoti's Year-End Virtual Investor Conference can greatly impact investor perception and stock performance.

First, the timing of these conferences is crucial. As they approach, investors typically reassess their positions, especially in biotech sectors where advancements can dramatically affect future valuations. The alpha-radiation therapy presented by Alpha Tau has the potential to redefine treatment protocols for solid tumors, making investors attentive to its efficacy and rationale. With CFO Raphi Levy presenting and available for 1x1 meetings, stakeholders will have the opportunity to gain insights directly from leadership regarding the therapeutic's clinical progress and commercialization strategy.

Second, investor interest in innovative cancer therapies is at an all-time high, driven by an aging global population and increasing cancer incidences. Alpha Tau’s targeted approach minimizes harm to surrounding healthy tissues, a vital point to underscore during conference discussions. This unique value proposition should resonate with investors looking for companies that offer differentiated solutions in a crowded market.

In light of the above, I advise current and potential investors to closely monitor Alpha Tau's performance leading up to and following these conferences. Engaging with the company's updates and leveraging the investor meetings could provide critical insights into Alpha DaRT's trajectory. Given the innovations they are presenting, a bullish outlook could be warranted—especially if positive data or partnerships are announced during or shortly after these events. As always, investors should balance their enthusiasm with caution and consider their risk tolerance.